ClinicalTrials.gg
RecruitingNCT07425080HELIOS-AUpdated Nov 9, 2026

HELIOS Advanced: Human Embryo Illumination to Enhance Development

An interventional study of Photobiomodulation in IVF Outcomes, sponsored by Columbia University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 48 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Columbia University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 9, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 48 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.

Planned enrollment
52nd of 274
270 · median 84
Started
2026
with 16 others
No phase
168 of 395
24 open now
Primary completion
2027-06
later than 34 of 82 live
Registered
386th of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 52nd largest by planned enrollment of the 274 interventional ones that give a count, is one of 17 that started in 2026, is one of 168 with no phase, reaches primary completion later than 34 of the 82 other live ones, and was the 386th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 48 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

As women get older, the "power plants" of the cells (called mitochondria) don't work as well. This makes it harder for eggs and embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses a special type of red light that boosts energy production in cells and helps them stay healthy. This study will test whether adding this light treatment during in vitro fertilization (IVF) can improve embryo growth and pregnancy outcomes.

Read the detailed description

Embryo development is highly energy-dependent, and impaired mitochondrial function is a well-established hallmark of reproductive aging. As women age, reactive oxygen species (ROS) accumulate and cause mitochondrial DNA (mtDNA) damage, leading to reduced oxidative phosphorylation, ATP (Adenosine 5'-triphosphate) depletion, and developmental arrest of embryos. Enhancing mitochondrial function represents a promising strategy to improve embryo quality, particularly in women of advanced maternal age.

Photobiomodulation (PBM), also known as low-level light therapy (LLLT), involves the application of low-intensity red or near-infrared (NIR) light to modulate mitochondrial activity. NIR light specifically activates cytochrome c oxidase, leading to increased ATP production, reduced oxidative stress, and improved cellular resilience. Numerous preclinical studies, including isolated mitochondria, cell cultures, and in vivo animal models, have confirmed the safety and efficacy of NIR light in restoring mitochondrial function without inducing DNA damage or chromosomal abnormalities.

The investigators previously conducted IRB-approved laboratory studies using mouse and donated human embryos, demonstrating that brief exposure to PBM improved blastocyst formation without adversely affecting chromosomal status.

The current study builds upon this foundational work to evaluate the clinical impact of PBM at the oocyte stage. In a randomized, blinded, sibling-embryo design, the investigators will test whether PBM improves fertilization rates, blastocyst formation, embryo quality, and pregnancy outcomes in participants undergoing IVF or ICSI (Intracytoplasmic sperm injection) with PGT-A (preimplantation genetic testing for aneuploidy) using their autologous oocytes.

03

Conditions studied

  • IVF Outcomes

Browse trials for

Keywords

  • Infertility
  • Embryo arrest
  • Fertility
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years to 48 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female age between 18-48 years at the time of the IVF/ICSI cycle
  • Undergoing blastocyst culture
  • Using own oocytes
  • Has at least two cleavage stage embryos available for randomization on Day 3 of embryo development
  • Consenting to embryo level randomization
  • Plan to transfer euploid embryo within 6 months

Exclusion criteria

Exclusion Criteria:

  • Use of donor oocytes or gestational carrier
  • Concurrent experimental laboratory inventions outside of protocol
  • Refusal of randomization or request for non-standard handling
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
270 participants (estimated)

Study arms

  • No intervention
    No photobiomodulation

    Participants will receive the same treatment (IVF/ICSI cycles with PGT-A). Participant's resultant cleavage stage embryos will be randomized to not receive PBM.

  • Experimental
    Photobiomodulation

    Participants will receive the same treatment (IVF/ICSI cycles with PGT-A). Participant's resultant cleavage stage embryos will be randomized to receive PBM.

    Other: Photobiomodulation

Interventions

  • OtherPhotobiomodulation

    Photobiomodulation (PBM): also known as low-level light therapy (LLLT), involves the application of low-intensity red or near-infrared (NIR) light to modulate mitochondrial activity.

06

What researchers measure

Primary outcomes

  1. Number of usable blastocysts

    Usable blastocysts are defined as blastocysts that can be biopsied and frozen on Day 5, 6, or 7 of development for PGT-A (pre-implantation genetic testing for aneuploidy). The study will calculate the usable blastocyst rate per oocyte retrieved defined as the number of usable blastocysts per cleavage stage embryo on Day 3.

    Time frame: Seven days post egg retrieval

Secondary outcomes

  1. Time to 2-cell stage

    Time (hours) for embryo to reach the 2-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  2. Time to 3-cell stage

    Time (hours) for embryo to reach the 3-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  3. Time to 6-cell stage

    Time (hours) for embryo to reach the 6-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  4. Time to 8-cell stage

    Time (hours) for embryo to reach the 8-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  5. Time to morula

    Time (hours) for embryo to reach the morula stage from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  6. Time to start of blastulation

    Time (hours) for embryo to start blastulation from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  7. Time to blastocyst

    Time (hours) for embryo to reach the blastocyst stage from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  8. Time to hatching blastocyst

    Time (hours) for embryo to reach the hatching blastocyst stage from insemination/ICSI as assessed by embryology using time-lapse imaging.

    Time frame: Up to seven days post egg retrieval

  9. Number of good quality blastocysts as defined by Gardner grading system

    Final blastocyst quality at the time of cryopreservation (Day 5,6, or 7) will be assessed using the Gardner grading system, which consists of three parameters: expansion and hatching status (graded 1-6), inner cell mass (graded A-D), and trophectoderm (graded A-D). A good quality blastocyst will be defined as a blastocyst of grade 3BB or higher.

    Time frame: Up to seven days post egg retrieval

  10. Euploidy Rate

    The chromosomal ploidy status of cryopreserved blastocysts is assessed by the presence of two copies of each autosome and the expected complement of sex chromosomes. The euploidy rate is defined as the number of cryopreserved blastocysts that have the correct number of chromosomes divided by the total number of cryopreserved blastocysts.

    Time frame: Within 30 days post egg retrieval

  11. Proportion of Embryo Selected for Transfer

    In cases with no stated embryo sex preference, the proportion of cycles in which the embryo selected for transfer is from the PBM-treated group versus the control group will be reported.

    Time frame: Within 1 year post egg retrieval

  12. Implantation Rate

    Implantation rate is defined as the number of cycles with positive beta hCG (human chorionic gonadotropin) nine days or more post frozen embryo transfer divided by the total number of frozen embryo transfer cycles.

    Time frame: Within 1 year post egg retrieval

  13. Clinical pregnancy rate

    Clinical pregnancy rate is defined as the number of cycles with the presence of a gestational sac visualized on transvaginal ultrasound divided by the total number of frozen embryo transfer cycles.

    Time frame: Within 1 year post egg retrieval

  14. Miscarriage rate

    Miscarriage rate is defined as the number of cycles with clinical pregnancy losses divided by the number of cycles that had positive hCGs post frozen embryo transfer.

    Time frame: Within 1 year of egg retrieval

  15. Live birth rate

    Live birth rate is defined as the number of cycles with a live born infant after 24 weeks gestation divided by total number of frozen embryo transfer cycles.

    Time frame: Up to 2 years post egg retrieval

  16. Gestational Age at Delivery

    Total number of completed weeks and days of pregnancy, calculated using frozen embryo transfer date.

    Time frame: Up to 2 years post egg retrieval

  17. Birthweight

    The weight of the baby at birth in grams

    Time frame: Up to 2 years post egg retrieval

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 14 months is below that.

Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedHas at least two oocytescleavage stage embryos available for randomization on Day 3 of embryo development
  • EditedConsenting to oocyteembryo level randomization
Nov 9, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionNumber of usable blastocysts: how it is measured was reworded
Nov 9, 2026
Secondary outcomes
3 removed
What changed in the outcomes
  • RemovedMaturity RateTime frame: Up to seven days post egg retrieval
  • RemovedFertilization RateTime frame: Up to seven days post egg retrieval
  • RemovedtPNfTime frame: Up to seven days post egg retrieval
Nov 9, 2026
Contact
Study contact changed: removed l•••@cumc.columbia.edu · •••8282. See the current contact
Nov 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Columbia University Fertility Center · New York, United StatesContact l•••@cumc.columbia.edu · •••8282→none listedContact removed (no phone or email listed)
Nov 9, 2026
Title
HELIOS Advanced: Human OocyteEmbryo Illumination to Enhance Development
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedHas at least two oocytescleavage stage embryos available for randomization on Day 3 of embryo development
    • EditedConsenting to oocyteembryo level randomization
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionNumber of usable blastocysts: how it is measured was reworded
    Secondary outcomes 3 removed
    What changed in the outcomes
    • RemovedMaturity RateTime frame: Up to seven days post egg retrieval
    • RemovedFertilization RateTime frame: Up to seven days post egg retrieval
    • RemovedtPNfTime frame: Up to seven days post egg retrieval
    Contact Study contact changed: removed l•••@cumc.columbia.edu · •••8282. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Columbia University Fertility Center · New York, United StatesContact l•••@cumc.columbia.edu · •••8282→none listedContact removed (no phone or email listed)
    Title HELIOS Advanced: Human OocyteEmbryo Illumination to Enhance Development
    + 5 other changes: verification date, date precision, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07425080
Responsible party
Samuel Zev Williams (Director of Columbia University Fertility Center; Wendy D. Havens Associate Professor of Women's Health; Chief of the Division of Reproductive Endocrinology and Infertility at Columbia University Irving Medical Center, Columbia University) — Principal investigator
First posted
Feb 20, 2026
Start date
Mar 24, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Samuel Zev Williams, MD, PhD
Contact
zw2421@cumc.columbia.edu
646-756-8282
Samuel Zev Williams, MD/PhD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion